RT Journal Article SR Electronic T1 Joint EANM, SNMMI, and IAEA Enabling Guide: How to Set up a Theranostics Center JF Journal of Nuclear Medicine JO J Nucl Med FD Society of Nuclear Medicine SP 1836 OP 1843 DO 10.2967/jnumed.122.264321 VO 63 IS 12 A1 Herrmann, Ken A1 Giovanella, Luca A1 Santos, Andrea A1 Gear, Jonathan A1 Ozgen Kiratli, Pinar A1 Kurth, Jens A1 Denis-Bacelar, Ana M. A1 Hustinx, Roland A1 Patt, Marianne A1 Wahl, Richard L. A1 Paez, Diana A1 Giammarile, Francesco A1 Jadvar, Hossein A1 Pandit-Taskar, Neeta A1 Ghesani, Munir A1 Kunikowska, Jolanta YR 2022 UL http://jnm.snmjournals.org/content/63/12/1836.abstract AB The theranostics concept using the same target for both imaging and therapy dates back to the middle of the last century, when radioactive iodine was first used to treat thyroid diseases. Since then, radioiodine has become broadly established clinically for diagnostic imaging and therapy of benign and malignant thyroid disease, worldwide. However, only since the approval of SSTR2-targeting theranostics following the NETTER-1 trial in neuroendocrine tumors, and the positive outcome of the VISION trial has theranostics gained substantial attention beyond nuclear medicine. The roll-out of radioligand therapy for treating a high-incidence tumor such as prostate cancer requires the expansion of existing and the establishment of new theranostics centers. Despite wide global variation in the regulatory, financial and medical landscapes, this guide attempts to provide valuable information to enable interested stakeholders to safely initiate and operate theranostic centers. This enabling guide does not intend to answer all possible questions, but rather to serve as an overarching framework for multiple, more detailed future initiatives. It recognizes that there are regional differences in the specifics of regulation of radiation safety, but common elements of best practice valid globally.